9 hours Ago By ABMN Staff
Invesco Ltd. raised its holdings in Summit Therapeutics Inc. ( NASDAQ:SMMT – Free Report ) by 435.
7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 399,050 shares of the company’s stock after acquiring an additional 324,555 shares during the quarter. Invesco Ltd.
owned approximately 0.05% of Summit Therapeutics worth $7,121,000 as of its most recent SEC filing. Other large investors have also recently modified their holdings of the company.
Cerity Partners LLC grew its stake in shares of Summit Therapeutics by 13.8% in the fourth quarter. Cerity Partners LLC now owns 113,214 shares of the company’s stock worth $2,023,000 after purchasing an additional 13,772 shares during the last quarter.
Polymer Capital Management HK LTD acquired a new stake in shares of Summit Therapeutics in the fourth quarter valued at about $3,923,000. Wells Fargo & Company MN raised its position in shares of Summit Therapeutics by 79.2% during the fourth quarter.
Wells Fargo & Company MN now owns 95,265 shares of the company’s stock worth $1,700,000 after acquiring an additional 42,090 shares during the last quarter. Cinctive Capital Management LP acquired a new position in shares of Summit Therapeutics in the fourth quarter worth approximately $487,000. Finally, Headlands Technologies LLC bought a new stake in Summit Therapeutics in the fourth quarter valued at approximately $306,000.
Institutional investors own 4.61% of the company’s stock. Summit Therapeutics Stock Up 10.
4 % SMMT stock opened at $36.70 on Friday. The stock’s 50 day moving average is $20.
90 and its 200-day moving average is $20.10. Summit Therapeutics Inc.
has a twelve month low of $2.10 and a twelve month high of $36.91.
The firm has a market capitalization of $27.07 billion, a PE ratio of -131.07 and a beta of -0.
46. Analyst Ratings Changes SMMT has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Summit Therapeutics in a report on Wednesday.
HC Wainwright reissued a “buy” rating and set a $44.00 target price on shares of Summit Therapeutics in a research note on Tuesday, February 25th. Evercore ISI started coverage on Summit Therapeutics in a report on Wednesday, March 12th.
They set an “outperform” rating and a $30.00 price target for the company. Citigroup raised Summit Therapeutics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $23.
00 to $35.00 in a research note on Wednesday, March 26th. Finally, The Goldman Sachs Group started coverage on Summit Therapeutics in a research note on Friday, February 28th.
They set a “buy” rating and a $42.00 target price for the company. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company’s stock.
According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.40.
Get Our Latest Analysis on SMMT Summit Therapeutics Profile ( Free Report ) Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. Further Reading Want to see what other hedge funds are holding SMMT? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Summit Therapeutics Inc. ( NASDAQ:SMMT – Free Report ). Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.
com's FREE daily email newsletter ..
